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Protein Z is a vitamin K-dependent plasma protein that
acts as a cofactor for the inactivation of activated factor X
by forming a complex with a specific plasma protein Z-
dependent protease inhibitor [1]. Over the past years,
protein Z has been investigated in different prothrombo-
tic conditions, ranging from ischaemic cerebrovascular
disease through pregnancy complications to coronary
artery disease, and a role for altered levels of this protein
has been reported [2–4]. However, some uncertainties
regarding the real role of this protein on the occurrence of
such diseases still remain. In particular, the relationship
between this protein and the inflammatory pathway has
been scarcely investigated. Only two previous studies
have analysed the interaction between protein Z and
proinflammatory cytokines: in 1999 Undar et al. showed
an inverse correlation between protein Z and interleukin-
6 in patients with haematological malignancies [5], while
in 2002 Vasse et al., in an ‘in-vitro’ study, demonstrated
that protein Z biosynthesis by hepatic cells was only
weakly affected by some inflammatory cytokines [6].
Actually, the very broad range of protein Z levels shown
within the normal population suggests that protein Z may
act as an acute phase protein, possibly being regulated by
inflammatory cytokines. However, no clear data regard-
ing the interplay between inflammatory reactants and
protein Z in patients with atherosclerotic diseases are
present.
The aim of this study was to evaluate the time-course of
protein Z and interleukin-6 during and after an acute
coronary event, in order to give an insight into the relation-
ship between protein Z and the acute-phase state. We
therefore enrolled and prospectively followed 10 patientsopyright © Lippincott Williams & Wilkins. Unauth
0957-5235  2007 Lippincott Williams & Wilkins(eight men, two women; median age, 64 years) with acute
coronary syndrome who underwent primary percutaneous
coronary intervention (PCI) at the Catheterization Labora-
tory of the Department of Heart and Vessels of the
University of Florence. All the patients were followed
up over several time-points [baseline (i.e. before PCI),
36 h, 72 h, 1 month and 3 months after PCI], remaining free
from any adverse events throughout the follow-up period,
and receiving standard therapy that included aspirin, clo-
pidogrel, low-molecular-weight heparin, intravenous
nitrates, statins, b-blockers and angiotensin-converting
enzyme inhibitors where appropriate. Study approval
was granted by the institutional ethics committee and
all patients gave written informed consent. None of the
patients were under anticoagulant treatment or reported a
positivity to factor V Leiden mutation or antiphospholipid
antibodies.
Fasting blood samples were withdrawn at each visit.
Protein Z plasma levels were measured as previously
described [4]. The intra-assay coefficient of variation
was 4.9% and the interassay coefficient of variation was
8.4%. Interleukin-6 plasma levels were measured using a
commercial enzyme-linked immunosorbent assay (high-
sensitivity interleukin-6 human, Biotrak ELISA system;
Amersham Biosciences, Little Chalfont, UK), according
to the manufacturer’s instructions.
Statistical analysis was performed using the SPSS soft-
ware for Windows (version 12.0; SPSS Inc., Chicago,
Illinois, USA). The Friedman test for related data was
used to evaluate differences among several time-points
for protein Z and interleukin-6 concentrations, whereas
the Wilcoxon test for paired data was used for compari-
sons between two different time-points. The Spearman
(R) test was used for correlation between the two
parameters.
Time-course modifications of protein Z and interleukin-6
are shown in Fig. 1. Overall, protein Z and interleukin-6
did not change significantly from baseline to 3 months
(P value for trend¼ 0.3 and 0.08, respectively). Protein Z,
however, showed a significant increase of concentration
up to a peak at 72 h after the acute event (P¼ 0.04, 72 h
versus baseline), returning to similar values with respect
to baseline and 3 months after the PCI, while interleukin-
6 showed a parallel pattern with an earlier but not
significant increase of values (P¼ 0.8, 36 h versus base-
line). In addition, correlation analyses showed a strong
positive correlation between protein Z and interleukin-6
at baseline and 3 months after the acute event (R¼ 0.85,
P¼ 0.002 and R¼ 0.89, P¼ 0.003).orized reproduction of this article is prohibited.
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Bold line, protein Z levels; dashed line, interleukin-6 levels.This is the first study that prospectively investigated, in a
limited number of patients with acute coronary syn-
drome, the time-course of protein Z during and after
an acute event, in relation to a highly sensitive inflam-
matory cytokine such as interleukin-6. Protein Z showed
a significant increase of values up to a peak at 72 h after
the acute coronary event. At 3 months of follow-up,
however, protein Z returned to similar values with
respect to baseline. This pattern was similar and parallel
to that reported by interleukin-6, which instead showed
an earlier peak of levels (i.e. at 36 h after PCI). Further-
more, correlation analyses demonstrated a strong positive
relationship between protein Z and interleukin-6 at base-
line, possibly suggesting a regulatory role of this cytokine
on protein Z hepatic biosynthesis. This datum seems to
be in accordance with that of Vasse et al., which showed a
significant, albeit modest, influence of inflammatory cyto-
kines on protein Z levels [6].
Several studies have to date demonstrated PCI to
represent a procedure that induces a prothrombotic state
and enhances the release of inflammatory markers, such
as C-reactive protein, tumour necrosis factor-a and inter-
leukin-6 [7–9]. It is therefore possible that protein Z
levels have been somehow influenced by this kind of
procedure. No ‘ad-hoc’ studies investigating the role of
PCI on influencing protein Z levels, however, have been
conducted. Besides, interleukin-6 has been recognized as
one of the principal regulator of most acute phase
proteins and a highly sensitive biomarker for detecting
early inflammatory response after coronary stent implan-
tation. The similar changes reported by protein Z over
follow-up points with regard to interleukin-6 seem to
indicate that protein Z is a weak acute-phase marker with
a longer latency time. Nonetheless, the reason why theopyright © Lippincott Williams & Wilkins. Unauthoacute phase is able to determine a delayed increase of
protein Z values with respect to inflammatory cytokines
remains to be solved. This ability could, however, partly
explain the conflicting findings reported for this protein
in relation to the occurrence of thrombotic diseases.
In conclusion, we reported in patients prospectively
followed up over several time points a characteristic
pattern of modifications for protein Z after an acute event.
In particular, a significant increase of values at 72 h after
the acute event has been reported, with a further
decrease up to similar values with respect to baseline
after 3 months. This characteristic pattern, if confirmed in
future and larger studies, seems to be of importance
in clinical studies evaluating protein Z in relation to
atherosclerotic diseases.
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It was with considerable interest that I read the recent
letter by Sheppard and colleagues [1]. These workers
observed a prolongation of routine coagulation test times
[prothrombin time and activated partial thromboplastin
time (APTT)] following filtration of plasma samples
intended for lupus anticoagulant testing, and thus iden-
tified this prolongation event as a novel preanalyticalrized reproduction of this article is prohibited.
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the mystery of the prolonged test times, tracking the
events to a particular batch lot of plasma filters, and to
consequent reduction in coagulation factor V (FV) and
factor VIII (FVIII). In the study by Sheppard and col-
leagues [1], the filtration of samples occurred ‘in-house’,
and thus the identification of the pre-analytical event was
achievable. Such ‘detective work’ is often employed by
many of us involved in haemostasis, when attempting to
solve a variety of inconsistencies in test results. Sheppard
and colleagues [1] have resolved this particular issue in
their laboratory by validating new filters prior to use.
These study findings deserve additional commentary. In
part, the report from Sheppard and colleagues [1] may
have under-emphasized the problem of preanalytical
variables related to filtration of samples. In addition,
there are a large number of other potential related pre-
analytical variable events that sometimes occur, which
were not reported in that previous communication.
In regards to the former, it should be recognized that
filtration of plasma samples can lead not only to iden-
tification of falsely prolonged prothrombin time and
APTT results, but also potentially to identification of
false FV and FVIII deficiencies. The identification of a
false FVIII deficiency (i.e. false diagnosis of haemophilia
A) is particularly relevant here. Our laboratory previously
identified the problem of sample filtration as a preana-
lytical problem some 10 years ago [2,3]. We also observed
prolongation of prothrombin time and APTT results
in filtered samples, as well as loss of FV and FVIII.
Additionally, in filtered plasma samples, we also observed
loss of factor IX and factor XII, and von Willebrand factor
(VWF). We were further able to show differential loss,
dependent on the point of sample filtration obtained
(i.e. greater losses identified in early filtration samples
compared with late filtration samples). This was presum-
ably due to initial adhesion or entrapment of these factors
by the filter, and eventual ‘filter saturation’ so that less
protein material was removed from the late filtration
sample. We also showed that loss of FVIII and VWF
was particularly striking, and that a false identification of
either haemophilia A or von Willebrand’s disease (VWD)
could ensue if the laboratory unknowingly tested filtered
plasma. This is a real possibility, particularly if samples
are derived from offsite sources.
The probable scenarios are as follows: (1) the routine
coagulation laboratory reports a prolonged coagulation
test time – either prior to filtration (e.g. normal range
variation event or true prolongation) or post filtration
event; (2) the clinician sees these results and requests
further investigation, and may order lupus anticoagulant
testing (a common reason for prolonged APTT results)
and/or factor assays to exclude a coagulation defect
(or haemophilia) and/or VWF studies to exclude VWD
(a common bleeding disorder that can sometimes presentopyright © Lippincott Williams & Wilkins. Unauthwith a prolonged APTT due to coincident FVIII
deficiency; (3) the sample processing laboratory filters
a plasma sample for lupus anticoagulant testing (as per
current guidelines and recommendations); and (4) the
specialized coagulation laboratory performs testing for
lupus anticoagulant and/or factor assay and/or VWF
testing. There are many possible failure points in this
process. Often, the routine coagulation laboratory, the
sample-processing laboratory, and the specialized coagu-
lation laboratory comprises two or three distinct labo-
ratories. The sample processing laboratory may not
appropriately differentially label any filtered (for lupus
anticoagulant) and nonfiltered (for factors and VWF)
plasma samples, or may fail to provide a nonfiltered
sample for coagulation factor/VWF testing. The special-
ized coagulation laboratory may unknowingly use a
filtered plasma sample for factor assay and VWF testing,
and thus report an abnormal finding. The clinician may
request repeat tests for confirmation. Unless the possi-
bility of the preanalytical event is recognized, however,
the same scenarios may eventuate, and the laboratory
may eventually report a similar (false) abnormal finding.
The clinician may thus unwittingly ‘diagnose’ haemo-
philia or VWD in their patient.
This situation is not restricted to filtration of plasma
samples. A similar finding of low FVIII and VWD-like
test results will occur if the laboratory tests serum
(instead of citrated plasma) [3], and low FVIII (and
FV) may also be identified (as well as possible inhibitors
to FV and FVIII) if ethylenediamine tetraacetic acid
plasma is used instead of citrated plasma [4]. Although
it may be expected that the likelihood of these events will
be low (and certainly lower than the likelihood of testing
filtered plasma), these events do occur in pathology
practice; most often, following collection into an inap-
propriate collection tube by inexperienced clinicians or
blood collectors, and/or provision of an inappropriate
specimen to the specialized coagulation laboratory by
the sample-processing laboratory [3,4]. The possibility of
these events is highest when the specialized coagulation
laboratory receives preprocessed samples from offsite
routine coagulation or sample processing laboratories
(i.e. the specialized coagulation laboratory does not see
the original collection tube).
Finally, another ‘generally unknown’ but ‘high-likeli-
hood/significant’ preanalytical problem is that of storage
or transport of samples destined for coagulation factor
and/or VWF testing. Current National Committee for
Clinical Laboratory Standards guidelines [5] recommend
that coagulation specimens be ‘kept at 2 to 48C or 18 to
248C’ until centrifuged and tested (within 4 h of collec-
tion). We and others [6–10], however, have now shown
that handling these specimens according to these guide-
lines can yield loss of FVIII and VWF (and thus a
false diagnosis of haemophilia or VWD) in a subset oforized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited
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CLetter to the editors 89individuals when samples are stored or transported at low
temperature. Samples stored at ambient temperature are
resistant to such events [6–11].
There is no doubt that other significant preanalytical
events may occur of which we are aware, or unaware
[12,13]. I have presented a summary of the information in
the current report in Table 1. In conclusion, it is import-
ant that collection staff, laboratory staff and clinical staff
are all aware of the possibility of such events, and that
mechanisms exist to avoid these situations. It is also
important to follow established guidelines on sample
processing [5], taking into account the caveats already
noted. In the case of Sheppard and colleagues [1], some
filter batch lots were found to be more problematic than
others, and those problematic filters will be avoided. We
did not study the possibility of filter variability in our
previous studies [2,3]. Alternate solutions to filtration
would be to double centrifuge samples, or to provide
separate labelled samples for lupus anticoagulant (filtered
or double centrifuged) and factor/VWF testing (standard
processing). Since the object of sample processing for
lupus anticoagulant testing is the provision of platelet-
free material, double centrifugation is an acceptable alter-
native to filtration, and simply involves the initial stan-
dard centrifugation step, separating and recentrifugation
of the separated plasma, and isolation and freezing of the
double-centrifuged plasma from any residual cell pellet.
We also reiterate that refrigerated transport of whole-
blood coagulation samples should be avoided if possible.
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